Thrombotic issues in transgender medicine: A review

Joseph J. Shatzel, Kara Connelly, Thomas Deloughery

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Clinicians, including hematologists, are more frequently encountering transgender individuals in practice; however, most lack training on the management and complications of transgender medicine. Hormonal therapy forms the backbone of medical interventions for patients undergoing gender transition. While supplementing an individual's intrinsic sex hormone is associated with a variety of hematologic complications including increased rates of venous thrombosis, cardiovascular events, erthyrocytosis, and malignancy, the risks of supplementing with opposing sex hormones are not well understood. Data on the hematologic complications of these therapies are accumulating but remain limited, and clinicians have little experience with their management. This review highlights the current interventions available in transgender medicine and related potential hematologic complications, and it suggests simple, evidence-based management going forward. Am. J. Hematol. 92:204–208, 2017.

Original languageEnglish (US)
Pages (from-to)204-208
Number of pages5
JournalAmerican Journal of Hematology
Volume92
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Transgender Persons
Medicine
Gonadal Steroid Hormones
Venous Thrombosis
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Thrombotic issues in transgender medicine : A review. / Shatzel, Joseph J.; Connelly, Kara; Deloughery, Thomas.

In: American Journal of Hematology, Vol. 92, No. 2, 01.02.2017, p. 204-208.

Research output: Contribution to journalReview article

@article{6d18a2dd9fbc44dbb3da08fbe2df23d2,
title = "Thrombotic issues in transgender medicine: A review",
abstract = "Clinicians, including hematologists, are more frequently encountering transgender individuals in practice; however, most lack training on the management and complications of transgender medicine. Hormonal therapy forms the backbone of medical interventions for patients undergoing gender transition. While supplementing an individual's intrinsic sex hormone is associated with a variety of hematologic complications including increased rates of venous thrombosis, cardiovascular events, erthyrocytosis, and malignancy, the risks of supplementing with opposing sex hormones are not well understood. Data on the hematologic complications of these therapies are accumulating but remain limited, and clinicians have little experience with their management. This review highlights the current interventions available in transgender medicine and related potential hematologic complications, and it suggests simple, evidence-based management going forward. Am. J. Hematol. 92:204–208, 2017.",
author = "Shatzel, {Joseph J.} and Kara Connelly and Thomas Deloughery",
year = "2017",
month = "2",
day = "1",
doi = "10.1002/ajh.24593",
language = "English (US)",
volume = "92",
pages = "204--208",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Thrombotic issues in transgender medicine

T2 - A review

AU - Shatzel, Joseph J.

AU - Connelly, Kara

AU - Deloughery, Thomas

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Clinicians, including hematologists, are more frequently encountering transgender individuals in practice; however, most lack training on the management and complications of transgender medicine. Hormonal therapy forms the backbone of medical interventions for patients undergoing gender transition. While supplementing an individual's intrinsic sex hormone is associated with a variety of hematologic complications including increased rates of venous thrombosis, cardiovascular events, erthyrocytosis, and malignancy, the risks of supplementing with opposing sex hormones are not well understood. Data on the hematologic complications of these therapies are accumulating but remain limited, and clinicians have little experience with their management. This review highlights the current interventions available in transgender medicine and related potential hematologic complications, and it suggests simple, evidence-based management going forward. Am. J. Hematol. 92:204–208, 2017.

AB - Clinicians, including hematologists, are more frequently encountering transgender individuals in practice; however, most lack training on the management and complications of transgender medicine. Hormonal therapy forms the backbone of medical interventions for patients undergoing gender transition. While supplementing an individual's intrinsic sex hormone is associated with a variety of hematologic complications including increased rates of venous thrombosis, cardiovascular events, erthyrocytosis, and malignancy, the risks of supplementing with opposing sex hormones are not well understood. Data on the hematologic complications of these therapies are accumulating but remain limited, and clinicians have little experience with their management. This review highlights the current interventions available in transgender medicine and related potential hematologic complications, and it suggests simple, evidence-based management going forward. Am. J. Hematol. 92:204–208, 2017.

UR - http://www.scopus.com/inward/record.url?scp=85009773778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009773778&partnerID=8YFLogxK

U2 - 10.1002/ajh.24593

DO - 10.1002/ajh.24593

M3 - Review article

C2 - 27779767

AN - SCOPUS:85009773778

VL - 92

SP - 204

EP - 208

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -